Skip to main content
. 2017 Dec 19;16:159. doi: 10.1186/s12933-017-0640-5

Fig. 3.

Fig. 3

Forest plot of hazard ratio of risk of new-onset AF for DM patients treated with metformin plus DPP-4 inhibitor versus other hypoglycemic agents after propensity score weighting. DPP4i is shown to be associated with a lower risk of new-onset AF compared with other hypoglycemic agents in most subgroups. DPP4i dipeptidyl peptidase-4 inhibitor